Annual report pursuant to Section 13 and 15(d)

Statements of Cash Flows

v3.7.0.1
Statements of Cash Flows - USD ($)
5 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2016
Cash Flows from Operating Activities:    
Net loss $ (748,360) $ (3,926,361)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 0 6,162
Stock-based compensation 0 323,974
Deferred CEO compensation   87,500
Stock issued for licenses used for research and development 2,061 0
Changes in operating assets and liabilities:    
Prepaid expenses   (215,052)
Accounts payable and accrued expenses 322,790 (41,128)
Net Cash Used in Operating Activities (423,509) (3,764,905)
Cash Flows from Investing Activities:    
Cash paid for purchase of fixed assets 0 (21,470)
Cash paid for acquisition of Moleculin, LLC, net with cash acquired 0 (99,638)
Net Cash Used in Investing Activities 0 (121,108)
Cash Flows from Financing Activities:    
Proceeds from notes payable 450,000 165,000
Payments on notes payable 0 (469,939)
Proceeds from sale of common stock, net of cash stock issuance costs 1,600 9,170,077
Net Cash Provided by Financing Activities 451,600 8,865,138
Net change in cash and cash equivalents 28,091 4,979,125
Cash and cash equivalents, at beginning of period 0 28,091
Cash and cash equivalents, at end of period 28,091 5,007,216
Supplemental disclosures of cash flow information:    
Cash paid for interest 0 4,585
Cash paid for income taxes 0 0
Supplemental disclosure of non-cash investing and financing activities:    
Common stock issued for the Acquisition of Moleculin, LLC 0 9,773,586
Common stock issued for conversion of debt 0 363,792
Warrants issued for services provided   374,763
Common stock issued for services provided   157,680
Shares subscribed $ 3,000 $ 0